Clinical Trials in Rheumatology
|
|
- Bertina Rose
- 5 years ago
- Views:
Transcription
1
2
3 Clinical Trials in Rheumatology
4 Rüdiger Müller Johannes von Kempis Clinical Trials in Rheumatology
5 Authors Rüdiger Müller Division of Rheumatology and Rehabilitation Department of Internal Medicine Kantonsspital St. Gallen Switzerland Johannes von Kempis Division of Rheumatology and Rehabilitation Department of Internal Medicine Kantonsspital St. Gallen Switzerland ISBN e-isbn DOI / Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: Springer-Verlag London Limited 2011 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: estudiocalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (
6 To our wives, and children: Sophia, and Franziska, Alexandra, Johanna, Antonius, Helena Johannes von Kempis Elke, and Ismene, Frederik and Mostafa Farmand, who was an inspiration to me during medical school Rüdiger Müller
7 Foreword Over the past 20 years, rheumatologists have developed and witnessed many paradigmatic changes not only in the medication of rheumatoid arthritis (RA) but also in other autoimmune rheumatic diseases. With regard to RA, less joint damage and better physical function has been demonstrated as a consequence of an early institution of disease-modifying anti-rheumatic drugs. Furthermore, the definition of core set variables and developments of composite measurements to assess RA have allowed disease activity to be assessed reliably. Finally, new biologic active agents have shown to be of major importance for fulfilling the aim of low disease activity or even remissions, specifically if treatment is commenced at a very early stage of the disease. These obvious significant advances in the treatment options for RA and other autoimmune rheumatic diseases would not have been made possible without a new culture for conducting clinical trials starting in the mid-1980s. The book Clinical Trials in Rheumatology provides a comprehensive overview of trials in different rheumatic diseases. It presents many important clinical trials conducted over the last 40 years, ranging from complex, double-blinded or open multicentric trials, e.g., the BeSt-study to case studies in situations where real trials are still missing. The different clinical trials to rheumatologic disease entities as listed in the book are not directly comparing outcome and clinical efficacy, or giving therapeutic recommendations. (For therapeutic decisions, the authors recommend to follow national and international guidelines and ongoing discussions concerning different treatment strategies in different autoimmune rheumatic diseases.) Instead, the book presents a well-founded and comprehensive selection of the most important studies. The authors present the relevant information concerning study design, medications, patient populations, clinical endpoints, and adverse events, thus offering a quick overview on the clinical trials conducted in different autoimmune rheumatic diseases. This new form of presenting the significant data of the most important studies in a comparable form renders this book a valuable help in the constantly growing multitude of clinical data in rheumatology. Prof. J. R. Kalden University of Erlangen vii
8 Preface The simple goal of this book is to provide a comprehensive overview of clinical trials in rheumatology in an easily readable manner. The constantly growing and increasingly confusing multitude of clinical trials in inflammatory rheumatic diseases first gave us the idea. This tremendous number of trials has been rendered possible by a steep increase in therapeutic options, such as the new therapeutic group of biologics, over roughly the last decade and by the development of more generally accepted response parameters. Many of the studies presented here were part of the clinical development program of biologics such as the TNF-inhibitors for different rheumatic diseases. They are complemented by studies with the same and older drugs, many of them investigator initiated, in different disease stages, e.g. in RA, or clinical situations, e.g. in vasculitis. The main idea of this survey in the beginning simply was to set up a list of studies named with an acronym, such as ATTAIN, ATTRACT, BeSt etc., in inflammatory joint disorders. We wanted to have such an acronym finder ready at hand at all times during the clinical day, in the laboratory and at scientific meetings. But during the selection process, more and more trials without an acronym either came to mind or appeared during online searches on public databases including ones about non-biologic DMARD in arthritis, autoimmune connective tissue diseases and vasculitis which seemed equally important. The result of all this evolutionary process is the present compilation which presents short summaries of the most relevant studies in a certain disease, without interpretation or valuation of the data. All types of studies are included, controlled prospective as well as observational ones case studies even where real studies are still missing. We did, however, exclude analyses of cohort data except for some prominent examples. We have concentrated on autoimmune inflammatory disorders and have not included studies on inflammatory metabolic diseases. Some of the studies in this book, e.g. in Sjögren s syndrome, don t fulfill the requirements of a modern drug trial, mostly due to the lack of accepted and specific response criteria. Our intention, however, was to list the relevant trials for every immunomodulatory drug in a certain disease, regardless of the trial s characteristics. For every study listed we tried to present the relevant information with regard to study design and substances used, patient population, clinical endpoints, and adverse events, and nevertheless to stay within a ix
9 x Preface one study-one page format wherever possible. Our focus was set on clinical, not laboratory outcomes. Changes in laboratory parameters are presented in some studies, however, but only if absolute numbers -as opposed to values presented in graphs- were available. Studies mainly represent the time span between the late 80ies and the beginning of 2010, but some historically interesting ones dating back to the seventies or even earlier are included. To hold up a simple survey principle, data are neither interpreted nor commented. Sometimes, however, details not mentioned in the original publication, such as changes in a certain parameter in percent, are added. The studies are listed by disease and compound, at the end of the book a list of acronyms and of abbreviations, respectively, used throughout the text is provided. We have made considerable efforts to reach all holders of copyright material and received permissions from all we have been able to make contact with. In only very few our repeated efforts have remained without answer. We would like to emphasize that we are not comparing studies. We are also definitely not giving therapeutic recommendations. For therapeutic decisions we recommend to follow national or international guidelines and the ongoing discussion concerning treatment strategies for the different diseases. This book presents our personal selection and we may well have missed important studies. We are planning to regularly update this book and welcome any suggestions, including for additional studies to be included, if they help improving the present format, preferably by . Rüdiger Müller Johannes von Kempis St. Gallen
10 How to Read This Book Trials are listed by disease according to the table of contents. In ANCA-associated vasculitis, at the beginning of a trial summary, different disease entities are listed if the trial investigated a mixture of vasculitides affecting vessels of different sizes according to the CHC-definitions. The sequence within a disease is corticosteroid trials at the beginning, followed by non biologic DMARDs in alphabetical order and trials with biologics, again alphabetically, after DMARD-trials. Several trials with one substance are presented in chronological order, beginning with the earliest. Trial Title of the publication as published Acronym: In case of an acronym, it s meaning is explained Substance Name of substances (biologic or pharmaceutic), doses used, and patient numbers in each treatment group, according to study design Only trials of registered substances or substances with far advanced registration process Concomitant medication: Additional medication permitted in the trial if mentioned in the original publication Previous medication: Medication before start of trial if mentioned in the original publication Result The main results are shortly summarized, mostly in compliance with the authors conclusions. Speculations the authors may have based on their findings are left out Patients The number of patients, the diseases treated, and, if adding to the clinical meaning of the study, details of the patient disposition at study entry, are specified The use of terms such as RA or SLE, without other details leading to the diagnosis, generally signifies that these patients fulfilled the most generally accepted international classification criteria, e.g., the ACR-criteria for RA Important inclusion and exclusion criteria are listed in some cases Authors Names according to original publication Publication Original citation xi
11 xii How to Read This Book Follow up Total follow up of the trial as defined or seen in the publication In many trials the follow up differed from the duration of the trial s treatment arms. In many of those trials, the duration of the trial can be seen under Substance ACR 20/50/70 In RA trials with these endpoints, the ACR response criteria are listed Note The data defined by the authors as study end points are presented as percentages or precise numbers, depending on their description in the publication, for every treatment group Changes from baseline, if available, are listed for every group Definitions of clear primary or secondary end points are restricted to more recent, controlled trials. For the sake of a standardized description scheme and to keep the trial summaries as short as possible, they are not named The same applies to informations on statistical significance, standard deviations, ranges, other methodologic details, definitions of remission, disease activity or relapse/flair and drop-out rates. For all these, please refer to the original publications Numbers either as absolute values (e.g., n = 1) or means (e.g., duration of symptoms: 40 months), if not mentioned otherwise Adverse events Adverse events are listed as described for every study drug or therapy regimen Contents
12 Contents Acronym-finder... xix Rheumatoid Arthritis... Corticosteroids... Atorvastatin... Azathioprine... Azathioprine vs. Methotrexate... Hydroxychloroquine vs. Sulphasalazine... Hydroxychloroquine... Chloroquine vs. Ciclosporin... Ciclosporin... Ciclosporin vs. Chloroquine... Ciclosporin vs. parenteral Gold... Ciclosporin... Ciclosporin vs. Methotrexate... Ciclosporin vs. Azathioprine... Cyclophosphamide... Gold vs. Methotrexate... Gold vs. Cyclophosphamide vs. Azathioprine... Leflunomide vs. Sulfasalazine... Methotrexate vs. Leflunomide... Sulfasalazine vs. Leflunomide... Leflunomide vs. Methotrexate... Leflunomide vs. Methotrexate... Methotrexate... Sulfasalazine... Sulfasalazine vs. Gold... Sulfasalazine... Tacrolimus xiii
13 xiv Contents Early DMARD therapy... Ciclosporin + Chloroquine... Methotrexate + Hydroxychloroquine... Methotrexate + Doxycycline... Methotrexate + Sulfasalazine... Methotrexate + Ciclosporin... Methotrexate + Hydroxychloroquine + Sulfasalazine... Methotrexate + Leflunomide... Methotrexate + Azathioprine... Gold + Methotrexate... Gold + Hydroxychloroquine... Abatacept... Etanercept + Abatacept... Adalimumab... Anakinra... Certolizumab pegol... Etanercept... Anakinra + Etanercept... Golimumab... Infliximab... Infliximab vs. Etanercept... Anti-TNF... Rituximab... Tocilizumab Ankylosing Spondylitis... Methylprednisolone... Cyclophosphamide... Methotrexate... Pamidronate... Sulfasalazine... Pred., Cyc., 5FU, MTX, MMF... Adalimumab... Etanercept... Infliximab vs. Etanercept... Golimumab... Infliximab Psoriatic Arthritis... Chloroquine... Ciclosporin vs. Methotrexate... Ciclosporine vs. Sulfasalazine... Ciclosporin ± Methotrexate
14 Contents xv Leflunomide vs. Methotrexate... Methotrexate... Sulfasalazine... Adalimumab... Alefacept... Etanercept... Golimumab... Infliximab... Ustekinumab Systemic Lupus Erythematosus... Corticosteroids... Azathioprine... Azathioprine vs. Ciclosporin... Chloroquine and Hydroxychloroquine... Hydroxychloroquine + Mycophenolate Mofetil... Cyclophosphamide vs. Azathioprine... Cyclophosphamide Followed by Azathioprine... Cyclophosphamide... Cyclophosphamide Followed by Azathioprine... Cyclophosphamide... Cyclophosphamide vs. Azathioprine... Methotrexate... Mycophenolate Mofetil vs. Cyclophosphamide, Azathioprine... Mycophenolate Mofetil... Mycophenolate or Azathioprine after Cyclophosphamide... Tacrolimus... Infliximab... Rituximab Antiphospholipid Syndrome... Aspirin... Aspirin vs. Heparin... Aspirin + Heparin... Aspirine + Prednisone... Aspirine vs. Prednisone... Heparin... Heparin vs. Prednisone... Heparin vs. intravenous Immunoglobulin... Intravenous Immunoglobulins... Warfarin Progressive Systemic Sclerosis Corticosteroids Ambrisentan
15 xvi Contents Azathioprine... Azathioprine + Cyclophosphamide... Bosentan... Chlorambucil... Ciclosprine... Colchicine... Cyclophosphamide... Cyclophosphamide vs. Azathioprine... Cyclophosphamide... D-Penicillamine... Methotrexate... Mycophenolate Mofetil... 5-Fluorouracil... Etanercept... Rituximab... Plasma Exchange... Stem Cell Transplantation... Autologous Stem Cell Transplantation Raynaud s Phenomenon... Diltiazem.... Glycerol Trinitrate... Iloprost... Nifedipine... Sildenafil Dermato/Polymyositis... Corticosteroids... Azathioprine... Cyclosphosphamide... Immunoglobulins... Methotrexate... Methotrexate vs. Ciclosporine... Mycophenolate Mofetil... Anti-TNF... Etanercept... Rituximab... Plasma Exchange Sjögren s syndrome... Hydroxychloroquine... Methotrexate... Mycophenolate
Antiphospholipid Syndrome Handbook
Antiphospholipid Syndrome Handbook Maria Laura Bertolaccini, Oier Ateka-Barrutia, and Munther A. Khamashta Antiphospholipid Syndrome Handbook Maria Laura Bertolaccini, MD, PhD Lupus Research Unit The Rayne
More informationRheumatoid Arthritis and Proteus
Rheumatoid Arthritis and Proteus Alan Ebringer Rheumatoid Arthritis and Proteus Alan Ebringer B.Sc., M.D., FRCP, FRACP, FRCPath Professor of Immunology King s College London and Honorary Consultant Rheumatologist
More informationEfim Benenson. Rheumatology. Clinical Scenarios. Syndrome or disease?
Rheumatology Efim Benenson Rheumatology Clinical Scenarios Syndrome or disease? Author Efim Benenson, MD Professor of Medicine Department of Internal Medicine University of Cologne Cologne Germany The
More informationHeart Failure in Congenital Heart Disease
Heart Failure in Congenital Heart Disease Robert E. Shaddy (Editor) Heart Failure in Congenital Heart Disease From Fetus to Adult Editor Robert E. Shaddy The Children s Hospital of Philadelphia School
More informationCancer Chemotherapy in Clinical Practice
Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Terry Priestman Terry Priestman, MD, FRCP, FRCR New Cross Hospital Wolverhampton UK British Library Cataloguing in Publication
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationClinical Echocardiography
Clinical Echocardiography Michael Y. Henein Editor Mary Sheppard John R. Pepper Michael Rigby Associate Editors Clinical Echocardiography Second Edition Editor Michael Y. Henein, M.D. Department of Public
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationHandbook of Blood Gas/Acid Base Interpretation
Handbook of Blood Gas/Acid Base Interpretation Ashfaq Hasan Handbook of Blood Gas/Acid Base Interpretation 13 Ashfaq Hasan Care Institute of Medical Sciences Banjara, Hyderabad India ISBN: 978-1-84800-333-0
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationSpringer London Berlin Heidelberg New York Barcelona Budapest Hong Kong Milan Paris Santa Clara Singapore Tokyo
Focus on Cancer Springer London Berlin Heidelberg New York Barcelona Budapest Hong Kong Milan Paris Santa Clara Singapore Tokyo Robert Dunlop Cancer: Palliative Care, Springer Robert Dunlop St Christopher's
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationProposed Retirement for HEDIS : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)
Proposed Retirement for HEDIS 1 2020 2 : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) NCQA seeks public comment on the proposed retirement of the Disease-Modifying Anti-Rheumatic
More informationAtlas of Staging in Gynecological Cancer
Atlas of Staging in Gynecological Cancer J. Richard Smith Jeremiah Healy Giuseppe Del Priore (Eds) Atlas of Staging in Gynecological Cancer J. Richard Smith, MB, ChB, MD, FRCOG West London Gynaecological
More informationBrain CT Scans in Clinical Practice
Brain CT Scans in Clinical Practice Brain CT Scans in Clinical Practice Usiakimi Igbaseimokumo With 109 Figures, 50 in Full Colour 123 Usiakimi Igbaseimokumo Division of Neurosurgery University of Missouri
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationEffective Health Care Program
Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationCompetency-Based Critical Care
Competency-Based Critical Care Series Editors John Knighton, MBBS, MRCP, FRCA Consultant Intensive Care Medicine & Anaesthesia Hospitals NHS Trust Paul Sadler, MBChB, FRCA Consultant Critical Care Medicine
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More informationHomocysteine. Related Vitamins and Neuropsychiatric Disorders
Homocysteine Related Vitamins and Neuropsychiatric Disorders Springer Paris Berlin Heidelberg New York Hong Kong London Milan Tokyo Christina Bolander-Gouaille Teodoro Bottiglieri Homocysteine Related
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More informationNovel anti-inflammatory compounds for ulcerative colitis and rheumatoid arthritis therapy
Novel anti-inflammatory compounds for ulcerative colitis and rheumatoid arthritis therapy JANSA, P. 1, HOLÝ, A. 1, ZÍDEK, Z. 2, JANEBA, Z. 1, KOLMAN, V. 1 1 Institute of Organic Chemistry and Biochemistry
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationWater-soluble Vitamin Assays in Human Nutrition
Water-soluble Vitamin Assays in Human Nutrition Water-soluble Vitamin Assays in Human Nutrition G.F.M. Ball SPRINGER-SCIENCE+BUSINESS MEDIA, B.V. First edition 1994 1994 Springer Science+Business Media
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationSine Syndromes in Rheumatology
Sine Syndromes in Rheumatology Jozef Rovenský Manfred Herold Martina Vašáková Editors Sine Syndromes in Rheumatology Editors Jozef Rovenský National Institute of Rheumatic Diseases Piešťany Slovakia Institute
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:
Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationBiologics in rheumatic diseases
Biologics in rheumatic diseases Dimitrios A. Vassilopoulos, MD Joint Rheumatology Program Clinical Immunology-Rheumatology Unit 2 nd Department of Medicine and Laboratory National and Kapodistrian University
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationCLINICAL EVIDENCE MADE EASY
CLINICAL EVIDENCE MADE EASY M HARRIS, G TAYLOR & D JACKSON THE BASICS OF EVIDENCE-BASED MEDICINE CLINICAL EVIDENCE MADE EASY CLINICAL EVIDENCE MADE EASY M. Harris General Practitioner and Visiting Senior
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationBioavailability and Analysis of Vitamins in Foods
Bioavailability and Analysis of Vitamins in Foods JOIN US ON THE INTERNET VIA WWW, GOPHER, FTP OR EMAIL: WWW: http://www.thomson.com GOPHER: gopher.thomson.com FTP: ftp.thomson.com EMAIL: findit@kiosk.thomson.com
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2018
Updates to the Alberta Drug Benefit List Effective January 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationRequest for Special Authorization Enbrel
Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. Special Authorization requires that you request approval from Great-West Life for
More informationLONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016
LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS Hong Kan 7/12/2016 1 Acknowledgements Research conceptualization and design, programming
More information2017 Medicare STARs Provider Quality Indicators Guide
2017 Medicare STARs Provider Quality Indicators Guide Medicare STARs Rating Centers for Medicare & Medicaid Services (CMS) created a Five-Star Quality Rating System to help measure the quality in care
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationEvidence-based Practice Center Systematic Review Protocol
Evidence-based Practice Center Systematic Review Protocol Project Title: Comparative Effectiveness of Drug Therapy for Psoriatic Arthritis in Adults Update Amendment Date(s) if applicable: (Amendments
More informationRheumatology Suggested Reading List. Compiled by Rebecca Sharim MD. Updated: 4/6/17
Rheumatology Suggested Reading List Compiled by Rebecca Sharim MD Updated: 4/6/17 Rheumatoid Arthritis: 1994: Elliott, Michael J., et al. "Randomised double-blind comparison of chimeric monoclonal antibody
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationPrinciples of Hearing Aid Audiology
Principles of Hearing Aid Audiology Principles of Hearing Aid Audiology Maryanne Tate I a 11 I Springer-Science+Business Media, B. v. First edition 1994 Maryanne Tate 1994 Originally published by Maryanne
More informationVaricella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus
Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus Helena M. Tabery Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus In Vivo Morphology in the Human Cornea
More informationManagement of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers
Management of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers Dominick George Sudano, MD Assistant Professor of Medicine Department of Rheumatology University of Arizona Objectives
More informationBRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1
BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended
More informationRisk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study
Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j895 (Published
More informationBy: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager:
For Use in: By: For: Guidelines for the Management of Interruption of Biologic Therapies for Division responsible for document: Key words: Name and job title of document author: Name and job title of document
More informationSexually Transmissible Infections in Clinical Practice
Sexually Transmissible Infections in Clinical Practice Alexander McMillan Sexually Transmissible Infections in Clinical Practice A Problem-Based Approach 123 Alexander McMillan, MD, FRCP Formerly, Consultant
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationCone Beam CT of the Head and Neck
Cone Beam CT of the Head and Neck Chung How Kau Kenneth Abramovitch Sherif Galal Kamel Marko Bozic Cone Beam CT of the Head and Neck An Anatomical Atlas Professor Chung How Kau University of Alabama Birmingham
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a
More information13. Behçet s - In Children
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk 13. Behçet s - In Children How are children affected by Behçet s disease? Behçet s disease (also
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More information